All In Biotech

Drug Trial Radar · NCT06983028

Atacicept in Multiple Glomerular Diseases

A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Jul 7, 2025

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Vera Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.

Conditions

  • pMN
  • IgAN
  • Nephrotic Syndrome
  • MCD
  • FSGS

Interventions

  • AtaciceptDrug

    Atacicept 150 mg SC QW via pre-filled syringe

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AE profile and results of routine clinical and laboratory testsTime frame: Baseline until end of study: 52 + 26 Weeks
  2. Percent reduction in urine protein to creatinine ratio (UPCR)Time frame: Baseline, Week 36

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vera Therapeutics

    Brisbane, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.